VRXAVeraxa Biotech AG Ordinary Shares
1.950USDMkt Cap: 275.75M $P/E: —3d ago
VERAXA Biotech AG develops antibody-based therapeutics and antibody-drug conjugates for cancer treatment. The company develops antibody-based therapeutics, including antibody-drug conjugates and bispecific antibody forma…
Industry Peers
Biotechnology$138.82BUSDP/E 31.9
$85.87BUSDP/E 20.5
$61.34BUSDP/E 39.8
$65.05BUSDP/E 39.6
$57.94BUSD
$45.95BUSDP/E 19.6
$44.89BUSD
$42.36BUSDP/E 67.2
$35.43BUSDP/E 32.6
$31.61BUSDP/E 41.2
$29.28BUSD
$27.47BUSD
$26.22BUSD
$25.91BUSDP/E 16.2
$20.86BUSDP/E 26.3
$19.26BUSDP/E 26.6
$16.61BUSDP/E 19.6
$16.51BUSDP/E 17.4
$15.93BUSD
$13.40BUSDP/E 17.0
Key Statistics
Company
Market Cap275.75M $
Enterprise Value—
Revenue (TTM)—
Gross Profit15.46K $
Net Income (TTM)-66.61M $
Revenue/Share—
Last Price1.950 USD
Fiscal Year End—
MR Quarter—
Employees—
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B—
EPS (TTM)-0.59
EPS (Forward)—
52W Range
1.85067% of range2.000
52W High2.000 USD
52W Low1.850 USD
Profitability
Gross Margin66.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin-284359.22%
ROE422.51%
ROA-82.42%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-9.90M $
CapEx (TTM)437.18K $
FCF Margin—
FCF Yield—
Net Debt—
Net Debt/EBITDA—
Balance Sheet
Debt/Equity-0.14
Current Ratio—
Quick Ratio—
Book Value/Sh—
Cash/Share—
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.141.41M
Float—
Insiders71.15%
Institutions2.05%
Short Interest
Short Ratio0.4d
Short % Out.0.28%
Shares Short240.55K
Short (prev mo.)131.85K
Technical
SMA 504.183 (-53.4%)
SMA 2009.317 (-79.1%)
Beta—
S&P 52W Chg21.00%
Avg Vol (30d)80.18K
Avg Vol (10d)89.87K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—